Evidence map›Paper›PMID 15249995›Full record

ArticleDiabetologia2004

Mutation analysis of suppressor of cytokine signalling 3, a candidate gene in Type 1 diabetes and insulin sensitivity.

T Gylvin, R Nolsøe, T Hansen, E M D Nielsen, R Bergholdt, A E Karlsen, N Billestrup, K Borch-Johnsen, O Pedersen, T Mandrup-Poulsen and 2 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Diabetologia, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

T GylvinSteno Diabetes Center, Niels Steensensvej 2-4, 2820, Gentofte, Denmark.
R NolsøeSteno Diabetes Center, Niels Steensensvej 2-4, 2820, Gentofte, Denmark.
T HansenSteno Diabetes Center, Niels Steensensvej 2-4, 2820, Gentofte, Denmark.
E M D NielsenSteno Diabetes Center, Niels Steensensvej 2-4, 2820, Gentofte, Denmark.
R BergholdtSteno Diabetes Center, Niels Steensensvej 2-4, 2820, Gentofte, Denmark.
A E KarlsenSteno Diabetes Center, Niels Steensensvej 2-4, 2820, Gentofte, Denmark.
N BillestrupSteno Diabetes Center, Niels Steensensvej 2-4, 2820, Gentofte, Denmark.
K Borch-JohnsenSteno Diabetes Center, Niels Steensensvej 2-4, 2820, Gentofte, Denmark.
O PedersenSteno Diabetes Center, Niels Steensensvej 2-4, 2820, Gentofte, Denmark.
T Mandrup-PoulsenSteno Diabetes Center, Niels Steensensvej 2-4, 2820, Gentofte, Denmark.
J NerupSteno Diabetes Center, Niels Steensensvej 2-4, 2820, Gentofte, Denmark.
F PociotSteno Diabetes Center, Niels Steensensvej 2-4, 2820, Gentofte, Denmark. fpoc@steno.dk.
Steno Diabetes Center · DKAarhus University · DKKarolinska Institutet · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aims/hypothesisBeta cell loss in Type 1 and Type 2 diabetes mellitus may result from apoptosis and necrosis induced by inflammatory mediators. The suppressor of cytokine signalling (SOCS)-3 is a natural inhibitor of cytokine signalling and also influences insulin signalling. SOCS3 could therefore be a candidate gene in the development of Type 1 and Type 2 diabetes mellitus.

methodsMutation analysis of the SOCS3 gene was performed in 21 patients with Type 1 diabetes mellitus and in seven healthy subjects. An identified promoter variant was examined in (i) 250 families with Type 1 diabetic family members (1097 individuals); (ii) 212 glucose-tolerant first-degree relatives of Type 2 diabetic patients; and (iii) 370 population-based young, healthy subjects who were unrelated.

resultsThree mutations were identified in the promoter region, but none in the coding region or the 3'UTR. Two of the three mutations had allele frequencies below 1% whereas the C -920-->A substitution had a minor allele frequency of 8%. In the group of young healthy subjects the insulin sensitivity index was higher among homozygous carriers of the A-allele than among heterozygous and wild-type subjects ( p=0.027, uncorrected). The same trend was found in the group of first-degree relatives of Type 2 diabetic patients. No association or linkage was found to Type 1 diabetes mellitus. CONCLUSIONS/

interpretationHomozygosity for the A-allele of the C -920-->A promoter polymorphism of the SOCS3 gene may be associated with increased whole-body insulin sensitivity, but deserves further investigation.

Indexed as

AdolescentAdultBase SequenceChildChild, PreschoolDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2DNA Mutational AnalysisDNA PrimersFamilyHumansInfantInsulinPolymerase Chain ReactionPolymorphism, Single NucleotideRepressor ProteinsDNA PrimersInsulinRepressor ProteinsSOCS3 protein, humanSuppressor of Cytokine Signaling 3 ProteinSuppressor of Cytokine Signaling ProteinsTranscription Factors

Identifiers

PMID15249995
OpenAlexW1995247729

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.